← Rocket Pharmaceuticals, Inc. (RCKT) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Rocket Pharmaceuticals, Inc. (RCKT)
Pharmaceutical Preparations · market cap $349M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Rocket Pharmaceuticals (RCKT) is a clinical-stage gene therapy company with a $444M market cap and two Phase 2 assets: RP-L201 for Leukocyte Adhesion Defect Type I (LAD-I) and RP-L102 for Fanconi Anemia Complementation Group A (FA-A). The company is in acute financial distress with only $49.6M in cash and a stated runway of 3.3 months, zero revenue, and cumulative net losses exceeding $1.1B over the past five years.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| RP-L201 | Phase 2 | Leukocyte Adhesion Defect - Type I |
| RP-L102 | Phase 2 | Fanconi Anemia Complementation Group A |
Price & technical context
3-month
-35.3%
6-month
-27.3%
12-month
-18.4%
52-wk range
$2.58–$5.30
vs 50-day MA
-23.2%
vs 200-day MA
-27.6%
Realized vol
71.4%
Max drawdown
-89.3%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RCKT (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.